LAKEWOOD, COLO., and BOCA RATON, Fla., U.S.A. - APRIL 19, 2021 - Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device began earlier this month, and introduction of the new platform is subject to U.S. Food and Drug Administration device clearance, at which time the parties will provide further comment.
Plasma is a key ingredient for therapies crucial to treating patients around the world suffering from a host of life-threatening conditions, such as primary immune deficiencies, hereditary angioedema, autoimmune diseases, hemophilia and inherited respiratory disease. Plasma is also commonly given to patients experiencing trauma, burns and organ transplant surgeries.
About CSL Plasma
CSL Plasma operates one of the world's largest and most sophisticated plasma collection networks, with more than 300 plasma collection centers in U.S., Europe and China. Plasma collected at CSL Plasma centers is used by CSL Behring for the purpose of manufacturing and delivering its life-saving therapies to people suffering from serious and rare diseases in more than 100 countries.
CSL Plasma, headquartered in Boca Raton, Fla., upholds a tradition of innovation and customer focus. We are committed to our work because people's lives depend on us. CSL Plasma is a subsidiary of CSL Behring, a global biotherapeutics company and a member of the CSL Group of companies.
The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 27,000 people, and delivers its life-saving therapies to people in more than 100 countries. For more information about CSL Plasma, please go to www.CSLPlasma.com.
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our associates around the world believe in the potential of blood and cells to do even more for patients than they do today. TERUMOBCT.COM
Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE:4543) , based in Tokyo.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.